KRAS vaccine (Targovax TG-01/Stimulon QS-21)

N/A

Report date: 2023/09/04 20:08:23

Base Information

Drug NameKRAS vaccine (Targovax TG-01/Stimulon QS-21)
Drug Alias NameN/A
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulantsT lymphocytes stimulantsRAS gene modulators
TargetsNot applicable
Therapy Area/IndicationsSmoldering Multiple MyelomaCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNorwayUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGeorgetown University (The)Targovax AsaAgenus Inc
China Registration ClassN/A

Develop Information

Active CompaniesGeorgetown UniversityTargovax Asa
Inactive CompaniesTragara Pharmaceuticals Inc
Active IndicationsSmoldering Multiple MyelomaCarcinoma, Non-Small-Cell LungPancreatic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A